Table 1. Loperamide use in the year before randomization: pooled analysis for eluxadoline phase 3 studies.
| Placebo (n=809) | Eluxadoline 75 mg (n=808) | Eluxadoline 100 mg (n=806) | |
|---|---|---|---|
| Prior loperamide use, n (%) | 282 (34.9) | 295 (36.5) | 296 (36.7) |
| Patients reporting inadequate control of IBS-D symptoms with prior loperamide,a n (%) | 166 (58.9) | 198 (67.1) | 174 (58.8) |
| Loperamide usage pattern,a n (%) | |||
| Acuteb | 249 (88.3) | 252 (85.1) | 250 (84.5) |
| Chronicc | 33 (11.7) | 43 (14.5) | 46 (15.5) |
IBS-D, irritable bowel syndrome with diarrhea.
a
Percentages expressed as a proportion of patients with prior loperamide use.
b
Acute use defined as use for short-term relief, typically not exceeding 6 days of consecutive daily use.
c
Chronic use defined as continuous use for maintenance therapy, typically exceeding ≥2 weeks of consecutive daily use.